ACRO Biomedical Co., Ltd.

[On Demand]
Search General Info
Search Education
Search Partnering Companies
ACRO Biomedical was founded in June 2014 in Kaohsiung, Taiwan. ACRO Biomedical uses its proprietary supercritical CO₂ extraction technology to remove cells, fat, and non-collagenous proteins from animal tissues and organs, while leaving the intact collagen scaffolds as the biomaterial for high-end medical devices in the field of wound care, orthopedics, dentistry, ophthalmology, aesthetic microsurgery, cardiovascular, and neural surgery, etc.
Besides from the development of natural biomaterial scaffolds for tissue engineering, ACRO Biomedical has advanced in combining these tissue scaffolds with stem cells and/or somatic cells for human cell therapy.
The ultimate goal for ACRO Biomedical is whole organ engineering for heart, liver, and kidney transplantation. We wish to recellularize the organ scaffold in vivo for autologous organ transplantation by grafting the decellularized natural organ scaffolds back into the live animal or human body.
Company Type:
Privately Funded Company
Company HQ State:
Not Provided
Company HQ Country:
Taiwan
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
cartilage graft
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
ACRO Biomedical Co., Ltd.